跳至主要内容

Active metabolomics: exploring metabolic activity in organisms

Active metabolomics is a scientific method to study the activity of metabolites in organisms. It analyzes the changes in metabolites in organisms to understand the metabolic state of organisms under specific physiological or pathological conditions. The use of active metabolomics to identify bioactive metabolites can help us deeply understand the metabolic process of organisms, discover new drug targets, and study the occurrence and development mechanisms of diseases.

The following are general steps for identifying bioactive metabolites using active metabolomics:

1. Sample collection: Collect biological samples in different physiological or pathological states, such as cells, tissues, blood, urine, etc.

2. Metabolite extraction: Extract metabolites from the sample. Commonly used methods include solvent extraction, solid phase extraction, etc.

3. Metabolite analysis: Use chromatography-mass spectrometry and other techniques to analyze the extracted metabolites to obtain information such as the molecular weight and mass spectrum of the metabolites.

4. Metabolite identification: Metabolites are identified by comparing known metabolite databases, mass spectra and other information.

5. Biological activity measurement: For the identified active metabolites, biological activity measurement can be performed to determine its physiological or pathological function.

6. Result analysis: Combine the identification results of metabolites and biological activity measurement results to analyze the metabolic state of the organism and explore its role in the occurrence and development of diseases.

Through the above steps, we can use active metabolomics to identify bioactive metabolites, further understand the metabolic processes and functions of organisms, and provide new ideas and methods for drug development and disease treatment.

The MetID team of Medicilon is composed of experienced scientists. We provide fast and reliable in vivo and in vitro MetID and reactive metabolite capture services. We also support new drug screening and domestic and oversees IND filings. Since the establishment of MetID team, Medicilon has successfully completed multiple different types of research projects for clients, including challenging peptide MetID research.


评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...